This database contains 175 studies, archived under the term: "administration & dosage"
Click here to filter this large number of results.
Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease
Zhong, Yuan,
Zheng, Xueli,
Miao, Ya,
Wan, Lili,
Yan, Hong,
Wang, Beiyun
Background: The aim of this study was to evaluate the effect of CYP2D6*10 and APOE polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of donepezil in patients with mild-to-moderate Alzheimer’s disease (AD).; Methods: A total of 110 Chinese AD patients participated in this study. Patients were treated with 5 to 10 mg of […]
Inhaled sevoflurane may promote progression of amnestic mild cognitive impairment: a prospective, randomized parallel-group study
Liu, Yongzhe,
Pan, Ningling,
Ma, Yaqun,
Zhang, Shengshuo,
Guo, Wenzhi,
Li, Haihong,
Zhou, Jingli,
Liu, Gang,
Gao, Minglong
Background: Amnestic mild cognitive impairment (aMCI) is thought to be a transitional stage between normal aging and the development of Alzheimer’s disease (AD). Recent studies have suggested that the inhalational anesthetic isoflurane can induce caspase activation and apoptosis, increase aggregates of β-amyloid (Aβ) levels, and enhance Aβ aggregation. The aim of this study was to […]
Rivastigmine patch for treatment of Alzheimer’s disease in clinical practice in Thailand
Kulkantrakorn, Kongkiat,
Tanyakitpisal, Panas,
Towanabut, Somchai,
Dejthevaporn, Charungthai,
Rangseekajee, Poonsri,
Pongpakdee, Sunsanee,
Laptikultham, Somsak,
Rodprasert, Kritsada,
Setthawatcharawanich, Suwanna,
Thinkhamrop, Bandit
Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer’s disease (AD) and dementia associated with Parkinson’s disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand.; Methods: A multicentre, […]
An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer’s Disease
Guo, Qihao,
Zhou, Yan,
Wang, Chao-Jih,
Huang, Young-Ming,
Lee, Yi-Ta,
Su, Muh-Hwan,
Lu, Jiahong
Aim: Efficacy and safety of Cistanche tubulosa glycoside capsules (CTG capsule, Memoregain(®)) for treating Alzheimer’s disease (AD) were studied.; Methods: A total of 18 patients with AD administered with Memoregain(®) for 48 weeks were assessed for drug efficacy by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADLs), Blessed […]
Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results
Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]
Clinical stabilisation in neurodegenerative diseases: clinical study in phase II
Introduction: Neurodegenerative disorders, such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and multiple sclerosis (MS), are progressive pathological conditions in which current treatments have not proved to be effective at curbing their progress (clinical stabilisation). Although they have very different clinical characteristics, they share the same pathophysiological mechanisms of progression. We developed a compound designed […]